The Supreme Court of India stated during a public health hearing that macroeconomic considerations and commercial pharmaceutical interests cannot override citizens’ constitutional rights to affordable healthcare and preservation of life. A bench of justices delivered the sharp rebuke while examining regulatory mechanisms implemented by the Union government to control the market costs of life-saving medical treatments, essential pharmaceuticals, and chronic care therapies.
Government advocates submitted that the Centre maintains a calibrated economic pricing strategy intended to balance manufacturer research incentives with domestic drug affordability. The top court expressed dissatisfaction with widening pricing disparities between generic formulations and branded pharmaceutical products, observing that exorbitant medicine expenses frequently push vulnerable households into catastrophic medical debt. The bench directed the National Pharmaceutical Pricing Authority and the Ministry of Chemicals and Fertilizers to submit comprehensive status affidavits demonstrating how existing price caps are monitored and why critical oncology and cardiac therapies remain excluded from statutory price control lists.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.thehindu.com/news/national/sc-says-economic-policy-cannot-take-precedence-over-lives-as-centre-backs-calibrated-drug-price-controls/article71631892.ece